{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T14:16:41Z","timestamp":1725891401454},"publisher-location":"Berlin, Heidelberg","reference-count":24,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"type":"print","value":"9783642744327"},{"type":"electronic","value":"9783642744303"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1989]]},"DOI":"10.1007\/978-3-642-74430-3_32","type":"book-chapter","created":{"date-parts":[[2012,7,28]],"date-time":"2012-07-28T19:36:17Z","timestamp":1343504177000},"page":"280-283","source":"Crossref","is-referenced-by-count":1,"title":["Perphenazine Serum Levels in Patients on Standard Doses"],"prefix":"10.1007","author":[{"given":"F.","family":"Haffner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"32_CR1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/archpsyc.1988.01800250095013","volume":"45","author":"RJ Baldessarini","year":"1988","unstructured":"Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45: 79\u201391","journal-title":"Arch Gen Psychiatry"},{"key":"32_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/BF00431770","volume":"87","author":"L Bolvig Hansen","year":"1985","unstructured":"Bolvig Hansen L, Larsen NE (1985) Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacology (Berlin) 87: 16\u201319","journal-title":"Psychopharmacology (Berlin)"},{"key":"32_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/BF00432245","volume":"78","author":"L Bolvig Hansen","year":"1982","unstructured":"Bolvig Hansen L, Larsen NE, Gulmann N (1982) Dose-response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology (Berlin) 78: 112\u2013115","journal-title":"Psychopharmacology (Berlin)"},{"key":"32_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/clpt.1986.221","volume":"40","author":"K Br\u00f6sen","year":"1988","unstructured":"Br\u00f6sen K, Gram LF (1988) First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 40: 543\u2013549","journal-title":"Clin Pharmacol Ther"},{"key":"32_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/978-3-642-70140-5_11","volume-title":"Dyskinesia research and treatment","author":"DE Casey","year":"1985","unstructured":"Casey DE (1985) Tardine dyskinesia: reversible and irreversible. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia research and treatment. Springer, Berlin Heidelberg New York, pp 88\u201397"},{"key":"32_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/00007691-198204000-00005","volume":"4","author":"SG Dahl","year":"1982","unstructured":"Dahl SG (1982) Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effect. Ther Drug Monit 4: 33\u201340","journal-title":"Ther Drug Monit"},{"key":"32_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2165\/00003088-198611010-00003","volume":"11","author":"SG Dahl","year":"1986","unstructured":"Dahl SG (1986) Plasma level monitoring of antipsychotic drugs. Clinical utility. Clin Pharmacokinet 11: 36\u201361","journal-title":"Clinical utility. Clin Pharmacokinet"},{"key":"32_CR8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/978-3-642-71288-3","volume-title":"Clinical pharmacology in psychiatry","author":"SG Dahl","year":"1986","unstructured":"Dahl SG, Hals PA (1986) Pharmacokinetic and pharmacodynamic factors causing variability in response to neuroleptic drugs. In: Dahl SG, Gram LF, Paul SM, Potter WZ (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York, pp 266\u2013274"},{"key":"32_CR9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/cpt1977214437","volume":"21","author":"SG Dahl","year":"1977","unstructured":"Dahl SG, Strandjord RE (1977) Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21: 437\u2013448","journal-title":"Clin Pharmacol Ther"},{"key":"32_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2165\/00003088-197702040-00001","volume":"2","author":"LF Gram","year":"1977","unstructured":"Gram LF (1977) Plasma level monitoring of tricyclic antidepressant therapy. Clin Pharmacokinet 2: 237\u2013251","journal-title":"Clin Pharmacokinet"},{"key":"32_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/00007691-198204000-00003","volume":"4","author":"LF Gram","year":"1982","unstructured":"Gram LF, Pedersen OL, Kristensen CB, Bjerre M, Krag-Sorensen P (1982) Drug level monitoring in psychopharmacology: usefulness and clinical problems, with special reference to tricyclic antidepressants. Ther Drug Monit 4: 17\u201325","journal-title":"Ther Drug Monit"},{"key":"32_CR12","first-page":"494","volume":"37","author":"GE Hogarty","year":"1976","unstructured":"Hogarty GE, Ulrich RF, Mussare F, Aristigueta N (1976) Drug discontinuation among long-term successfully maintained schizophrenic outpatients. Dis Nerv Syst 37: 494\u2013500","journal-title":"Dis Nerv Syst"},{"key":"32_CR13","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/archpsyc.1979.01780120013001","volume":"36","author":"GE Hogarty","year":"1979","unstructured":"Hogarty GE, Schooler NR, Ulrich RF, Mussare F, Ferro P, Herron E (1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients. Arch Gen Psychiatry 36: 1283\u20131294","journal-title":"Arch Gen Psychiatry"},{"key":"32_CR14","first-page":"123","volume-title":"Patient compliance","author":"BS Hulka","year":"1976","unstructured":"Hulka BS, Cassel JC, Kupper LL (1976) Disparities between medications prescribed and consumed among chronic disease patients. In: Lasagna L (ed) Patient compliance. Futura Mount Kisco, New York, pp 123\u2013152"},{"key":"32_CR15","first-page":"111","volume-title":"Progress in drug metabolism","author":"A J\u00f8rgensen","year":"1986","unstructured":"J\u00f8rgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. In: Bridges JW, Chassaud LF (eds) Progress in drug metabolism, vol 9. Taylor and Francis, London, pp 111\u2013174"},{"key":"32_CR16","first-page":"16","volume":"46","author":"JM Kane","year":"1985","unstructured":"Kane JM (1985) Antipsychotic drug side effects: their relationship to dose. J Clin Psychiatry 46: 16\u201321","journal-title":"J Clin Psychiatry"},{"key":"32_CR17","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/archpsyc.1983.01790070083010","volume":"40","author":"JM Kane","year":"1983","unstructured":"Kane JM, Rifkin A, Woerner M, Reardon G, Sarantoakis S, Schibel D, Ramos-Lorenzi J (1983) Low dose neuroleptic treatment of outpatient schizophrenic patients. Arch Gen Psychiatry 40: 893\u2013896","journal-title":"Arch Gen Psychiatry"},{"key":"32_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/978-3-642-70140-5_9","volume-title":"Dyskinesia research and treatment","author":"JM Kane","year":"1985","unstructured":"Kane JM, Woerner M, Lieberman J (1985) Tardive dyskinesia: prevalence, incidence, and risk factors. In: Casey DE, Chase TN, Christensen AY, Gerlach J (eds) Dyskinesia research and treatment. Springer, Berlin Heidelberg New York, pp 72\u201378"},{"key":"32_CR19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S0378-4347(00)84037-2","volume":"341","author":"NE Larsen","year":"1985","unstructured":"Larsen NE, Bolving Hansen L, Knudsen P (1985) Quantitative determination of perphenazine and its dealkylated metabolite using high-performance liquid chromatography. J Chromatogr 341: 244\u2013250","journal-title":"J Chromatogr"},{"key":"32_CR20","volume-title":"May PRA","author":"SR Marder","year":"1984","unstructured":"Marder SR, van Putten T, Mintz J, McKenzie J, Lobell M, Faltico G, May PRA (1984)"},{"key":"32_CR21","doi-asserted-by":"crossref","unstructured":"Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 41: 1025\u20131029","DOI":"10.1001\/archpsyc.1983.01790220015002"},{"key":"32_CR22","first-page":"10","volume":"45","author":"RJ Neborsky","year":"1984","unstructured":"Neborsky RJ, Jankowski DS, Perel JM, Munson E, Depry DO (1984) Plasma\/RBC haloperidol ratios and improvement in acute psychotic symptoms. J Clin Psychiatry 45: 10\u201313","journal-title":"J Clin Psychiatry"},{"key":"32_CR23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archpsyc.1977.01770130045004","volume":"34","author":"A Rifkin","year":"1977","unstructured":"Rifkin A, Quitkin F, Robiner DJ, Klein DJ (1977) Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remittent schizophrenics. I. Relapse after one year. Arch Gen Psychiatry 34: 43\u201347","journal-title":"Arch Gen Psychiatry"},{"key":"32_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/00007691-198001000-00010","volume":"25","author":"F Sj\u00f8qvist","year":"1980","unstructured":"Sj\u00f8qvist F, Bertilsson L. Asberg M (1980) Monitoring tricyclic antidepressants. Ther Drug Monit 25: 85\u201393","journal-title":"Ther Drug Monit"}],"container-title":["Clinical Pharmacology in Psychiatry"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-74430-3_32.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T21:18:40Z","timestamp":1606252720000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-642-74430-3_32"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989]]},"ISBN":["9783642744327","9783642744303"],"references-count":24,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-74430-3_32","relation":{},"subject":[],"published":{"date-parts":[[1989]]}}}